BGB-A317-311

Active, not recruiting

Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC

Beigene Study ID info

BGB-A317-311

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20190198

Study Overview

Sex: All

Age: 18 Years to 75 Years   (Adult, Older Adult)

No Study Documents

Study Overview

Sex: All

Age: 18 Years to 75 Years   (Adult, Older Adult)

No Study Documents